

# UK guidelines on the management of iron deficiency in pregnancy

Sue Pavord,<sup>1</sup> Bethan Myers,<sup>2</sup> Susan Robinson,<sup>3</sup> Shubha Allard,<sup>4</sup> Jane Strong<sup>1</sup> and Christina Oppenheimer<sup>1</sup> on behalf of the British Committee for Standards in Haematology

<sup>1</sup>University Hospitals of Leicester, <sup>2</sup>United Lincolnshire Hospitals Trust, <sup>3</sup>Guy's and St Thomas' Hospital, and <sup>4</sup>Bart's and the London NHS Trust & NHS Blood and Transplant, London, UK

## Summary

Iron deficiency is the most common deficiency state in the world, affecting more than 2 billion people globally. Although it is particularly prevalent in less-developed countries, it remains a significant problem in the developed world, even where other forms of malnutrition have already been almost eliminated. Effective management is needed to prevent adverse maternal and pregnancy outcomes, including the need for red cell transfusion. The objective of this guideline is to provide healthcare professionals with clear and simple recommendations for the diagnosis, treatment and prevention of iron deficiency in pregnancy and the postpartum period. This is the first such guideline in the UK and may be applicable to other developed countries. Public health measures, such as helminth control and iron fortification of foods, which can be important to developing countries, are not considered here. The guidance may not be appropriate to all patients and individual patient circumstances may dictate an alternative approach.

**Keywords:** iron, iron depletion, iron deficiency, anaemia, pregnancy.

The guideline group was selected by the British Society for Haematology, Obstetric Haematology Group (BSH OHG) and British Committee for Standards in Haematology (BCSH), to be representative of UK-based medical experts. MEDLINE and EMBASE were searched systematically for publications from 1966 until 2010 using the terms iron, anaemia, transfusion and pregnancy. Opinions were also sought from experienced obstetricians and practice development midwives. The writing group produced the draft guideline, which was subsequently considered by the members of the BSH Obstetric Haematology Group and revised by consensus by members of the General Haematology Task Force of the BCSH. The guideline was then reviewed by a sounding board of approximately 50 UK

haematologists, the BCSH and the BSH Committee and comments incorporated where appropriate. Criteria used to quote levels of recommendation and grades of evidence are as outlined in the Procedure for Guidelines Commissioned by the BCSH.

## Summary of key recommendations

- Anaemia is defined by Hb <110 g/l in the first trimester, <105 g/l in the second and third trimesters and <100 g/l in the postpartum period.
- Full blood count (FBC) should be assessed at booking and at 28 weeks.
- All women should be given dietary information to maximize iron intake and absorption.
- **Routine iron supplementation for all women in pregnancy is not recommended in the UK.**
- Unselected screening with routine use of serum ferritin is generally not recommended although individual centres with a particularly high prevalence of 'at risk' women may find this useful.
- **For anaemic women, a trial of oral iron should be considered as the first line diagnostic test, whereby an increment demonstrated at 2 weeks is a positive result.**
- **Women with known haemoglobinopathy should have serum ferritin checked and offered oral supplements if their ferritin level is <30 µg/l.**
- Women with unknown haemoglobinopathy status with a normocytic or microcytic anaemia, should start a trial of oral iron (1B) and haemoglobinopathy screening should be commenced without delay in accordance with the National Health Service (NHS) sickle cell and thalassaemia screening programme.
- Non-anaemic women identified to be at increased risk of iron deficiency should have their serum ferritin checked early in pregnancy and be offered oral supplements if ferritin is <30 µg/l.
- Systems must be in place for rapid review and follow up of blood results.

Correspondence: Sue R. Pavord, c/o BCSH Secretary, British Society for Haematology, 100 White Lion Street, London N1 9PF, UK.  
E-mail [bcsh@b-s-h.org.uk](mailto:bcsh@b-s-h.org.uk)

First published online 16 January 2012  
doi:10.1111/j.1365-2141.2011.09012.x

© 2012 Blackwell Publishing Ltd  
*British Journal of Haematology*, 2012, **156**, 588–600

- Women with established iron deficiency anaemia should be given 100–200 mg elemental iron daily. They should be advised on correct administration to optimize absorption.
- Referral to secondary care should be considered if there are significant symptoms and/or severe anaemia (Hb <70 g/l) or late gestation (>34 weeks) or if there is failure to respond to a trial of oral iron.
- For nausea and epigastric discomfort, preparations with lower iron content should be tried. Slow release and enteric-coated forms should be avoided.
- Once Hb is in the normal range supplementation should continue for 3 months and at least until 6 weeks postpartum to replenish iron stores.
- Non-anaemic iron deficient women should be offered 65 mg elemental iron daily, with a repeat Hb and serum ferritin test after 8 weeks.
- Anaemic women may require additional precautions for delivery, including delivery in a hospital setting, available intravenous access, blood group-and-save, active management of the third stage of labour, and plans for excess bleeding. Suggested Hb cut-offs are <100 g/l for delivery in hospital and <95 g/l for delivery in an obstetrician-led unit.
- Women with Hb <100 g/l in the postpartum period should be given 100–200 mg elemental iron for 3 months.
- Parenteral iron should be considered from the second trimester onwards and during the postpartum period for women with confirmed iron deficiency who fail to respond to or are intolerant of oral iron.
- Blood transfusion should be reserved for those with risk of further bleeding, imminent cardiac compromise or symptoms requiring immediate attention. This should be backed up by local guidelines and effective patient information.
- Whenever iron tablets are supplied, the importance of keeping them out of the reach of children must be stressed.

## 1. Definition and prevalence of iron deficiency anaemia in pregnancy

### 1.1 Definition

Iron deficiency represents a spectrum ranging from iron depletion to iron deficiency anaemia. In iron depletion, the amount of stored iron (measured by serum ferritin concentration) is reduced but the amount of transport and functional iron may not be affected. Those with iron depletion have no iron stores to mobilize if the body requires additional iron. In iron-deficient erythropoiesis, stored iron is depleted and transport iron (measured by transferrin saturation) is reduced further; the amount of iron absorbed is not sufficient to replace the amount lost or to provide the amount needed for

growth and function. In this stage, the shortage of iron limits red blood cell production and results in increased erythrocyte protoporphyrin concentration. In iron-deficiency anaemia, the most severe form of iron deficiency, there is shortage of iron stores, transport and functional iron, resulting in reduced haemoglobin (Hb) in addition to low serum ferritin, low transferrin saturation and increased erythrocyte protoporphyrin concentration.

Anaemia is defined as Hb <2 standard deviations below the mean for a healthy matched population. However there is variation in what are considered normal values for pregnancy. The World Health Organization (WHO) defines anaemia in pregnancy as a haemoglobin concentration of <110 g/l (WHO, 2001) whereas large studies in Caucasians have found a range between 104 g/l and 135 g/l early in the third trimester, in women receiving iron supplements (Milman *et al*, 2007). In view of the relative plasma expansion being particularly marked in the second trimester, it would seem reasonable to take 105 g/l as the cut-off from 12 weeks, as suggested by the US Centers for Disease Control and Prevention (CDC) (Dowdle, 1989; Ramsey *et al*, 2000). However there is a racial difference in normal Hb levels and the optimum Hb may be lower in those of African origin than in Europeans (Garn *et al*, 1981).

The WHO defines postpartum anaemia as Hb <100 g/l (Cunningham & Pritchard, 1977; WHO 1992).

### Recommendation

**There is variation in definition of normal Hb levels in pregnancy. A level of  $\geq 110$  g/l appears adequate in the first trimester and  $\geq 105$  g/l in the second and third trimesters (1B). Postpartum anaemia is defined as Hb <100 g/l (2B).**

### 1.2 Prevalence

Anaemia affects 1.62 billion people globally, corresponding to 24.8% of the world population (McLean *et al*, 2009). Iron deficiency is the most common cause and even in the developed world an estimated 30–40% of preschool children and pregnant women have iron depletion (de Benoist *et al*, 2008).

## 2. Clinical effects of iron deficiency

Tissue enzyme malfunction occurs even in the early stages of iron-deficient erythropoiesis and significant effects of iron deficiency anaemia have been described on maternal morbidity and mortality, fetal and infant development and pregnancy outcomes.

### 2.1 Maternal morbidity and mortality

Iron deficiency may contribute to maternal morbidity through effects on immune function with increased susceptibility or severity of infections (Ekiz *et al*, 2005), poor work capacity and performance (Haas & Brownlie, 2001) and disturbances of

postpartum cognition and emotions (Beard *et al*, 2005). There is little information regarding the Hb thresholds below which mortality increases, although this may be as high as 8.9 g/dl, which was associated with a doubling of the maternal death risk in Britain in a 1958 study (Brabin *et al*, 2001). However severe anaemia is likely to have multiple causes and the direct effect of the anaemia itself is unclear.

### 2.2 Effects on the fetus and infant

The fetus is relatively protected from the effects of iron deficiency by upregulation of placental iron transport proteins (Gambling *et al*, 2001) but evidence suggests that maternal iron depletion increases the risk of iron deficiency in the first 3 months of life, by a variety of mechanisms (Puolakka *et al*, 1980; Colomer *et al*, 1990). Impaired psychomotor and/or mental development are well described in infants with iron deficiency anaemia and may also negatively contribute to infant and social emotional behaviour (Perez *et al*, 2005) and have an association with adult onset diseases, although this is a controversial area (Beard, 2008; Insel *et al*, 2008).

### 2.3 Effects on pregnancy outcome

There is some evidence for the association between maternal iron deficiency and preterm delivery, (Scholl & Hediger, 1994), low birth weight (Cogswell *et al*, 2003), possibly placental abruption and increased peripartum blood loss (Arnold *et al*, 2009). However further research on the effect of iron deficiency, independent of confounding factors, is necessary to establish a clear causal relationship with pregnancy and fetal outcomes.

## 3. Diagnosis of iron deficiency

### 3.1 Clinical symptoms and signs

Clinical symptoms and signs of iron deficiency anaemia in pregnancy are usually non-specific, unless the anaemia is severe. Fatigue is the most common symptom. Patients may complain of pallor, weakness, headache, palpitations, dizziness, dyspnoea and irritability. Rarely pica develops, where there is a craving for non-food items such as ice and dirt. Iron deficiency anaemia may also impair temperature regulation and cause pregnant women to feel colder than normal.

Storage iron is depleted before a fall in Hb and as iron is an essential element in all cells, symptoms of iron deficiency may occur even without anaemia: These include fatigue, irritability, poor concentration and hair loss.

### 3.2 Laboratory tests

**3.2.1 Full blood count, blood film and red cell indices.** A full blood count (FBC) is taken routinely in pregnancy and may show low Hb, mean cell volume (MCV), mean cell haemoglobin

(MCH), and mean cell haemoglobin concentration (MCHC); a blood film may confirm presence of microcytic hypochromic red cells and characteristic 'pencil cells'. However, microcytic, hypochromic indices may also occur in haemoglobinopathies. In addition, normal pregnancy is associated with a slight rise in MCV and for milder cases of iron deficiency, the MCV may not have fallen below the normal range.

Some haematological analysers will give a percentage of hypochromic red cells present. This is said to be a sensitive marker of functional iron deficiency, but is not available on all analysers, and there is little information on its use in pregnancy.

Other tests either assess iron stores or the adequacy of iron supply to the tissues.

**3.2.2 Serum ferritin.** Serum ferritin is a stable glycoprotein that accurately reflects iron stores in the absence of inflammatory change. It is the first laboratory test to become abnormal as iron stores decrease and it is not affected by recent iron ingestion. It is generally considered the best test to assess iron deficiency in pregnancy, although it is an acute phase reactant and levels will rise when there is active infection or inflammation.

During pregnancy, in women with adequate iron stores at conception, the serum ferritin concentration initially rises, followed by a progressive fall by 32 weeks to about 50% pre-pregnancy levels. This is due to haemodilution and mobilization of iron. The levels increase again mildly in the third trimester (Asif *et al*, 2007). Even though the ferritin level may be influenced by the plasma dilution later in pregnancy, a concentration <15 µg/l indicates iron depletion in all stages of pregnancy. In women of reproductive age, a level <15 µg/l has shown specificity of 98% and sensitivity of 75% for iron deficiency, as defined by no stainable bone marrow iron (Hallberg *et al*, 1993). There are a variety of levels for treatment, quoted in different studies but in general, treatment should be considered when serum ferritin levels fall below 30 µg/l, as this indicates early iron depletion, which will worsen unless treated. Van den Broek *et al* (1998) found that serum ferritin is the best single indicator of storage iron provided a cut-off point of 30 mg/l is used, with sensitivity of 90%, and specificity 85%. Concurrent measurement of the C-reactive protein (CRP) may be helpful in interpreting higher levels, where indicated. The CRP concentration seems to be independent of pregnancy and gestational age, although some studies describe a mild increase.

**3.2.3 Serum iron (Fe) and total iron binding capacity (TIBC).** Serum Fe and TIBC are unreliable indicators of availability of iron to the tissues because of wide fluctuation in levels due to recent ingestion of Fe, diurnal rhythm and other factors, such as infection. Transferrin saturation fluctuates due to a diurnal variation in serum iron and is affected by the nutritional status

(Adams *et al*, 2007). This may lead to a lack of sensitivity and specificity.

**3.2.4 Zinc protoporphyrin (ZPP).** ZPP increases when iron availability decreases, as zinc, rather than iron, is incorporated into the protoporphyrin ring. This gives an indication of availability of iron to the tissues. Serum ZPP has the advantage of not being influenced by the plasma dilution and levels rise in the third trimester. It is affected by inflammation and infection although less so than is the serum ferritin. Red blood cell ZPP has greater sensitivity and specificity for iron depletion (Schifman *et al*, 1989) but is rarely performed.

**3.2.5 Soluble transferrin receptor (sTfR).** Measurement of sTfR is reported to be a sensitive measure of tissue iron supply and is not an acute-phase reactant (Choi *et al*, 2000). The transferrin receptor is a transmembrane protein that transports iron into the cell. Circulating concentrations of sTfR are proportional to cellular expression of the membrane-associated TfR and therefore give an accurate estimate of iron deficiency. There is little change in the early stages of iron store depletion, but once iron deficiency is established, the sTfR concentration increases in direct proportion to total transferrin receptor concentration. However, this is an expensive test, which restricts its general availability, and there is little data on its use in pregnancy.

**3.2.6 Reticulocyte haemoglobin content and reticulocytes.** Iron deficiency causes a reduction in reticulocyte number and reticulocyte haemoglobin concentration. Using an automated flow-cytometry technique, measurements of reticulocyte cellular characteristics allow extremely early and objective information to be collected on erythropoietic activity in anaemia. This again is not widely available, and there is no data in pregnancy.

**3.2.7 Bone marrow iron.** A bone marrow sample stained for iron has been considered the gold standard for assessment of iron stores; however, this test is clearly too invasive and not practical for any but the most complicated cases in pregnancy, where the underlying cause or causes of anaemia are not identifiable by simpler means.

**3.2.8 Trial of iron therapy.** A trial of iron therapy is simultaneously diagnostic and therapeutic. Ferritin should be checked first if the patient is known to have a haemoglobinopathy but otherwise microcytic or normocytic anaemia can be assumed to be caused by iron deficiency until proven otherwise. Assessment of response to iron is both cost- and time-effective. A rise in Hb should be demonstrable by 2 weeks and confirms iron deficiency. If haemoglobinopathy status is unknown, it is reasonable to start iron whilst screening is being performed. Screening should be carried out immediately, in accordance with the NHS sickle cell and

thalassaemia screening programme guidelines (NHS Sickle Cell and Thalassaemia Screening Programme 2006). Although severe anaemia can affect the results of haemoglobinopathy testing, with a reduction in HbA<sub>2</sub> of up to 0.5%, there is no justification for delay (Ryan *et al*, 2010). An effective system of reviewing results is imperative. If there has been no improvement in Hb by 2 weeks, referral should be made to secondary care to consider other causes of anaemia, such as folate deficiency.

### Recommendations

**A trial of oral iron should be considered as the first line diagnostic test for normocytic or microcytic anaemia. An increase in Hb must be demonstrated at 2 weeks, otherwise further tests are needed (1B).**

**Serum ferritin should be checked prior to starting iron in patients with known haemoglobinopathy (1B).**

**Anaemic women with unknown haemoglobinopathy status should be offered a trial of iron (1B) and haemoglobinopathy screening should be undertaken without delay in accordance with the NHS sickle cell and thalassaemia screening programme guidelines (1A) but with awareness that iron deficiency can cause some lowering of the haemoglobin A<sub>2</sub> percentage.**

**The serum ferritin level is the most useful and easily available parameter for assessing iron deficiency. Levels below 15 µg/l are diagnostic of established iron deficiency. A level below 30 µg/l in pregnancy should prompt treatment (2A).**

**Where available, ZPP or sTfR measurements may be helpful adjuncts. Serum CRP levels may facilitate assessment when inflammatory or infective processes are suspected/present (2B).**

## 4. Management of iron deficiency

### 4.1 Dietary advice

The average daily iron intake from food for women in Great Britain is 10.5 mg (Gregory *et al*, 1990). Approximately 15% of dietary iron is absorbed. Physiological iron requirements are 3 times higher in pregnancy than they are in the menstruating woman (Tapiero *et al*, 2001), with increasing demand as pregnancy advances. The recommended daily intake (RDA) of iron for the latter half of pregnancy is 30 mg. Absorption of iron increases three-fold by the third trimester, with iron requirements increasing from 1–2 mg to 6 mg per day (Bothwell, 2000).

The amount of iron absorption depends upon the amount of iron in the diet, its bioavailability and physiological requirements. The main sources of dietary haem iron are haemoglobin and myoglobin from red meats, fish and poultry. Haem iron is absorbed 2- to 3-fold more readily than non-haem iron. Meat also contains organic compounds that

promote the absorption of iron from other less bioavailable non-haem iron sources (Skikne & Baynes, 1994). However approximately 95% of dietary iron intake is from non-haem iron sources (Ryan *et al*, 2010). Vitamin C (ascorbic acid) significantly enhances iron absorption from non-haem foods (Lynch, 1997), the size of this effect increasing with the quantity of vitamin C in the meal. Germination and fermentation of cereals and legumes improve the bioavailability of non-haem iron by reducing the content of phytate, a food substance that inhibits iron absorption. Tannins in tea and coffee inhibit iron absorption when consumed with a meal or shortly after (Table I).

Education and counselling regarding diet may improve iron intake and enhance absorption but the degree of change achievable, especially in poorer individuals, remains in question.

### Recommendation

**All women should be counselled regarding diet in pregnancy, including details of iron rich food sources and factors that may inhibit or promote iron absorption and why maintaining adequate iron stores in pregnancy is important. This should be consolidated by the provision of an information leaflet in the appropriate language (1A).**

## 4.2 Oral iron supplements

**4.2.1 Oral iron preparations.** Once women become iron-deficient in pregnancy it is not possible to ensure repletion through diet alone and oral supplementation is needed.

Oral iron is an effective, cheap and safe way to replace iron. Ferrous salts show only marginal differences between one another in efficiency of absorption of iron. Ferric salts are much less well absorbed. The recommended dose of elemental iron for treatment of iron deficiency is 100–200 mg daily. Higher doses should not be given, as absorption is saturated and side effects increased.

Available ferrous salts include ferrous fumarate, ferrous sulphate and ferrous gluconate. The amount of elemental iron in each salt varies, as detailed in Table II. Combined iron and folic acid preparations may also be used (Table III) but it should be noted that use of these preparations does not obviate the need to take the recommended dose of folic acid for

Table I. Factors influencing the absorption of iron.

Factors that inhibit iron absorption	Factors that enhance iron absorption
Foods rich in calcium	Haem iron
Tannins in tea	Ferrous iron (Fe <sup>2+</sup> )
Phytates in cereals	Ascorbic acid

Table II. Dose and elemental iron content per tablet of oral iron preparations.

Iron salt	Dose per tablet	Elemental iron
Ferrous Fumarate	200 mg	65 mg
Ferrous Gluconate	300 mg	35 mg
Ferrous Sulphate (dried)	200 mg	65 mg
Ferrous Sulphate	300 mg	60 mg
FerrousFeredetate (Sytron)	190 mg/5 ml elixir	27.5 mg/5 ml elixir

Table adapted from the British National Formulary (2010).

prevention of neural tube defects preconception and during the first 12 weeks of pregnancy.

Oral iron supplementation should be taken on an empty stomach, as absorption is reduced or promoted by the same factors that affect absorption of dietary non-haem iron.

### Recommendation

**Dietary changes alone are insufficient to correct iron deficiency anaemia and iron supplements are necessary. Ferrous iron salts are the preparation of choice. The oral dose for iron deficiency anaemia should be 100–200 mg of elemental iron daily (1A).**

**Women should be counselled as to how to take oral iron supplements correctly. This should be on an empty stomach, 1 h before meals, with a source of vitamin C (ascorbic acid) such as orange juice to maximize absorption. Other medications or antacids should not be taken at the same time (1A).**

**4.2.2 Indications for oral iron supplementation.** In keeping with the National Institute for Health and Clinical Excellence (NICE) clinical guidance for routine antenatal care, all women should have a full blood count taken at the booking appointment and at 28 weeks (NICE, 2008). This enables selective iron supplementation early in pregnancy but depends on effective systems in place for rapid review of blood results and appropriate follow up to avoid delays in management.

Women with a Hb <110 g/l up until 12 weeks or <105 g/l beyond 12 weeks should be offered a trial of therapeutic iron

Table III. Dose and elemental iron content per tablet of combined oral iron and folate preparations.

Combined iron and folate preparation	Iron salt and dose per tablet	Elemental iron content per tablet	Folic acid content per tablet
Pregaday	Fumarate 305 mg	100 mg	350 µg
Fefol	Sulphate 325 mg	47 mg	500 µg
Galfer FA	Fumarate 305 mg	100 mg	350 µg

replacement. In the presence of known haemoglobinopathy, serum ferritin should be checked and women offered therapeutic iron replacement if the ferritin is  $<30 \mu\text{g/l}$ .

Treatment must begin promptly in the community. Referral to secondary care should be considered if there are significant symptoms and/or severe anaemia (Hb  $<70 \text{ g/l}$ ) or advanced gestation ( $>34$  weeks) or if there is no rise in Hb at 2 weeks.

Women with a Hb  $>110 \text{ g/l}$  up until 12 weeks gestation and Hb  $>105 \text{ g/l}$  beyond 12 weeks are not anaemic. However experience in the UK suggests iron store depletion without anaemia is not well identified. In non-anaemic women at increased risk of iron depletion, such as those with previous anaemia, multiple pregnancy, consecutive pregnancies with less than a year's interval between and vegetarians, a serum ferritin should be considered (Table IV). Other patients to consider include pregnant teenagers, women at high risk of bleeding and Jehovah's witnesses.

If the ferritin is  $<30 \mu\text{g/l}$ , 65 mg elemental iron once a day should be offered. FBC and ferritin should be checked 8 weeks later.

Unselected screening with routine use of serum ferritin is generally not recommended, as this is an expensive use of resources, may be misused to exclude iron deficiency and may cause delay in response to blood count results. However local populations should be considered and where there is a particularly high prevalence of 'at-risk' women, this practice may be helpful.

### Recommendation

**FBC should be assessed at booking and at 28 weeks (1A).**

**Women with a Hb  $<110 \text{ g/l}$  before 12 weeks or  $<105 \text{ g/l}$  beyond 12 weeks are anaemic and should be offered a trial of therapeutic iron replacement, unless they are known to have a haemoglobinopathy (1B).**

**Women with known haemoglobinopathy should have serum ferritin checked and offered therapeutic iron if the ferritin is  $<30 \mu\text{g/l}$  (1B).**

**Treatment should start promptly in the community and referral to secondary care should be considered if anaemia is**

**severe (Hb  $<70 \text{ g/l}$ ) and/or associated with significant symptoms or advanced gestation ( $>34$  weeks) (2B). In these cases the starting dose should be 200 mg elemental iron daily.**

**In non-anaemic women at increased risk of iron depletion, serum ferritin should be checked. If the ferritin is  $<30 \mu\text{g/l}$ , 65 mg elemental iron once a day should be offered (1B).**

**Unselected screening with routine use of serum ferritin is generally not recommended although it may be useful for centres with a particularly high prevalence of 'at-risk' women (2B).**

**Systems must be in place for rapid review and follow up of blood results (1A).**

*4.2.3 Response to oral iron.* The haemoglobin concentration should rise by approximately 20 g/l over 3–4 weeks (British National Formulary, 2010). However, the degree of increase in Hb that can be achieved with iron supplements will depend on the Hb and iron status at the start of supplementation, ongoing losses, iron absorption and other factors contributing to anaemia, such as other micronutrient deficiencies, infections and renal impairment.

Compliance and intolerance of oral iron preparations can limit efficacy. Iron salts may cause gastric irritation and up to a third of patients may develop dose limiting side effects (Breyman, 2002), including nausea and epigastric discomfort. Titration of dose to a level where side effects are acceptable or a trial of an alternative preparation may be necessary. Enteric-coated or sustained release preparations should be avoided as the majority of the iron is carried past the duodenum, limiting absorption (Tapiero *et al*, 2001). The relationship between dose and altered bowel habit (diarrhoea and constipation) is less clear (Tapiero *et al*, 2001) and other strategies, such as use of laxatives are helpful.

A repeat Hb at 2 weeks is required to assess response to treatment. The timing of further checks will depend upon the degree of anaemia and period of gestation. Once the Hb is in the normal range, treatment should be continued for a further 3 months and at least until 6 weeks postpartum to replenish iron stores.

### Recommendation

**For nausea and epigastric discomfort, preparations with lower iron content should be tried. Slow release and enteric-coated forms should be avoided (1A).**

**Repeat Hb testing is required 2 weeks after commencing treatment for established anaemia, to assess compliance, correct administration and response to treatment (1B).**

**Once the haemoglobin concentration is in the normal range, replacement should continue for 3 months and until at least 6 weeks postpartum to replenish iron stores (1A).**

**In non-anaemic women repeat Hb and serum ferritin is required after 8 weeks of treatment to confirm response (2B).**

**Table IV** Indications for assessment of serum ferritin.

Anaemic women where estimation of iron stores is necessary
Known haemoglobinopathy
Prior to parenteral iron replacement
Non-anaemic women with high risk of iron depletion
Previous anaemia
Multiparity $\geq P3$
Consecutive pregnancy $<1$ year following delivery
Vegetarians
Teenage pregnancies
Recent history of bleeding
Non-anaemic women where estimation of iron stores is necessary
High risk of bleeding
Jehovah's witnesses

**If response to oral iron replacement is poor, concomitant causes that may be contributing to the anaemia, such as folate deficiency or anaemia of chronic disease, need to be excluded and the patient referred to secondary care (1A).**

**4.2.4 Postnatal anaemia.** The WHO define postnatal anaemia as Hb <100 g/l. FBC should be checked within 48 h of delivery in all women with an estimated blood loss >500 ml and in women with uncorrected anaemia in the antenatal period or symptoms suggestive of postpartum anaemia.

Women with Hb <100 g/l, who are haemodynamically stable, asymptomatic, or mildly symptomatic, should be offered elemental iron 100–200 mg daily for at least 3 months and a repeat FBC and ferritin to ensure Hb and iron stores are replete.

#### *Recommendation*

**Postpartum women with estimated blood loss >500 ml and uncorrected anaemia detected in the antenatal period or symptoms suggestive of anaemia postnatally should have their Hb checked within 48 h (1B).**

**Women who are haemodynamically stable, asymptomatic or mildly symptomatic, with Hb <100 g/l should be offered elemental iron 100–200 mg daily for 3 months with a repeat FBC and ferritin at the end of therapy to ensure Hb and iron stores are replete (1B).**

#### *4.3 Parenteral iron therapy*

Parenteral iron therapy is indicated when there is absolute non-compliance with, or intolerance to, oral iron therapy or proven malabsorption (RCOG, 2007). It circumvents the natural gastrointestinal regulatory mechanisms to deliver non-protein bound iron to the red cells.

Several authors have now reported on their experience with use of parenteral iron therapy for iron deficiency anaemia in pregnancy, with faster increases in Hb and better replenishment of iron stores in comparison with oral therapy, particularly demonstrated for iron sucrose (Al *et al*, 2005; Bhandal & Russell, 2006) and iron (III) carboxymaltose (Breyman *et al*, 2007; Van Wyk & Martens, 2007). A large retrospective study reported fewer postpartum transfusions in the group treated with intravenous (IV) iron (Broche *et al*, 2005). However, there is a paucity of good quality trials that assess clinical outcomes and safety of these preparations (Revez *et al*, 2007).

As free iron may lead to the production of hydroxyl radicals with potential toxicity to tissues, iron deficiency should be confirmed by ferritin levels before use of parenteral preparations. Contraindications include a history of anaphylaxis or reactions to parenteral iron therapy, first trimester of pregnancy, active acute or chronic infection and chronic liver disease (Perewusnyk *et al*, 2002). Facilities and staff trained in management of anaphylaxis should be available.

The intravenous iron preparations currently available in the UK and their properties are summarized in Table V (British National Formulary, 2010). The different preparations have not been compared to each other in pregnancy. Iron sucrose has a higher availability for erythropoiesis than iron dextran and experience suggests a good safety profile in pregnancy (Bayoumeu *et al*, 2005). Its use is limited by the total dose that can be administered in one infusion, requiring multiple infusions. The newer preparations, iron III carboxymaltose and iron III isomaltoside, aim to overcome this problem, with single dose administration in an hour or less (Lyseng-Williamson & Keating, 2009; Gozzard, 2011).

**4.3.1 Fast acting intravenous iron preparations.** Iron III carboxymaltose (Ferrinject) is a ferric hydroxide carbohydrate complex, which allows for controlled delivery of iron within the cells of the reticuloendothelial system (primarily bone marrow) and subsequent delivery to the iron binding proteins ferritin and transferrin. It is administered intravenously, as a single dose of 1000 mg over 15 min (maximum 15 mg/kg by injection or 20 mg/kg by infusion). Randomized controlled trials have shown non-inferiority (Breyman *et al*, 2007; Van Wyk & Martens, 2007) and superiority (Seid *et al*, 2008) to oral ferrous sulphate in the treatment of iron deficiency anaemia in the postpartum period, with rapid and sustained increases in Hb. Animal studies have shown it to be rapidly eliminated from the plasma, giving minimal risk of large amounts of ionic iron in the plasma. In iron deficient rats, most of the iron has been incorporated into new erythrocytes by 28 d (Funk *et al*, 2010).

Iron III isomaltoside (Monofer) is an intravenous preparation with strongly bound iron in spheroid iron-carbohydrate particles, providing slow release of bioavailable iron to iron binding proteins. There is rapid uptake by the reticuloendothelial system and little risk of release of free iron. An erythropoietic response is seen in a few days, with an increased reticulocyte count. Ferritin levels return to the normal range by 3 weeks as iron is incorporated into new erythrocytes. Doses >1000 mg iron can be administered in a single infusion (Gozzard, 2011), although there is little data on its use in the obstetrics setting.

**4.3.2 Intramuscular preparations.** The only preparation available in the UK that may be given intramuscularly (IM) is low molecular weight iron dextran. Compared with oral iron, IM iron dextran has been shown in a randomized controlled trial to reduce the proportion of women with anaemia (Komolafe *et al*, 2003). However injections tend to be painful and there is significant risk of permanent skin staining. Its use is therefore generally discouraged (Solomons & Schumann, 2004; Pasricha *et al*, 2010) but if given, the Z-track injection technique should be used to minimize risk of iron leakage into the skin. The advantage of IM iron dextran is that, following a test dose, it

Table V. Summary of intravenous iron preparations available in the UK.

	Cosmofer Iron (III) hydroxide dextran complex	Venofer Iron (III) hydroxide sucrose complex	Ferinject Iron(III) carboxymaltose	Monofer Iron (III) isomaltoside
Dose of elemental iron	50 mg/ml	20 mg/ml	50 mg/ml	100 mg/ml
Test dose required as per manufacturer	Yes, before every intravenous dose, once before intramuscular treatment	First dose new patients only	No	No
Routes of administration	Slow intravenous injection Intravenous infusion of total dose Intramuscular injection total dose	Slow intravenous injection Intravenous infusion	Slow intravenous injection Intravenous infusion	Slow intravenous injection Intravenous infusion
Able to administer total dose	Yes (up to 20 mg/kg bodyweight over 4–6 h)	No	Yes [up to 20 mg/kg bodyweight (maximum of 1000 mg/week) over 15 min] 7–12 h	Yes (up to 20 mg/kg bodyweight over 1 h)
Half-life	5 h	20 h	7–12 h	5 h
Dosage	100–200 mg per IV injection up to 3 times a week Total dose infusion up to 20 mg/kg bodyweight over 4–6 h (100 mg IM into alternate buttocks daily in active patients in bed ridden up to 3 times a week)	Total IV single dose no more than 200 mg, can be repeated up to 3 times in 1 week	1000 mg by IV injection up to 15 mg/kg per week Total dose infusion up to 20 mg/kg bodyweight. Maximum weekly dose of 1000 mg, which can be administered over 15 min.	100–200 mg per IV injection up to 3 times a week Total dose infusion up to 20 mg/kg body weight per week Doses up to 10 mg/kg bodyweight can be administered over 30 min, doses >10 mg/kg body weight should be administered over 60 min.
Use in pregnancy	No adequate data for use in pregnant women, contra-indicated in first trimester thereafter risk benefit based on clinical need	Not in first trimester	Avoid use in first trimester	No adequate data for use in pregnant women, contra-indicated in first trimester thereafter risk benefit based on clinical need
Lactation	Risk not known	Unlikely to pass to maternal milk no clinical trials	<1% iron passed into milk; unlikely to be significant	Risk not known
Adverse drug-related events	5% patients may experience minimal adverse events (dose related) Risk of severe anaphylaxis <1/10 000 Risk of anaphylactoid symptoms >1/1000 < 1/100	0.5–1.5% of patients may experience adverse events Risk of anaphylactoid reaction >1/10 000 < 1/1000	3% of patients may experience adverse events Risk of anaphylactoid reaction >1/1000 < 1/100	More than 1% of patients may experience adverse events Risk of anaphylaxis <1/10 000 >1/1000 to <1/100 Anaphylactoid reactions



can be administered in primary care, although facilities for resuscitation should be available as there is a small risk of systemic reaction.

**4.3.3 Other considerations.** A recent Cochrane review on treatments for iron deficiency in anaemia (Revez *et al*, 2007) highlighted the need for good quality randomized controlled trials in this setting, particularly for the assessment of clinical outcomes and adverse events. Pending further good quality evidence, there is a need for centres to review their policies and systems for use of parenteral therapy in iron deficiency anaemia in pregnancy.

#### *Recommendations*

**Parenteral iron should be considered from the second trimester onwards and postpartum period in women with iron deficiency anaemia who fail to respond to, or are intolerant of, oral iron (1A).**

**The dose of parenteral iron should be calculated on the basis of pre-pregnancy weight, aiming for a target Hb of 110 g/l (1B).**

**The choice of parenteral iron preparation should be based on local facilities, taking into consideration not only drug costs but also facilities and staff required for administration. All centres should undertake audit of utilization of intravenous iron therapy with feedback of results and change of practice where needed (1A).**

**Women should be informed of potential side effects and written information should be provided.**

### **5. Management of delivery in women with iron deficiency anaemia**

With good practice this situation should generally be avoided; however there are instances when women book late, have recently come from abroad or have not engaged with antenatal care. In these situations it may be necessary to take active measures to minimize blood loss at delivery. Considerations should be given to delivery in hospital, intravenous access and blood group-and-save. Whilst this should be done on an individual basis, a suggested cut off would be Hb <100 g/l for delivery in hospital, including hospital-based midwifery-led unit and <95 g/l for delivery in an obstetrician-led unit, with an intrapartum care plan discussed and documented.

Clear evidence from randomized trials supports active management of the third stage of labour as a method of decreasing postpartum blood loss (Prendiville *et al*, 1988; Rogers *et al*, 1998). This should be with intramuscular syntometrine/syntocinon and in the presence of additional risk factors, such as prolonged labour or instrumental delivery, an intravenous infusion of high dose syntocinon continued for 2–4 h to maintain uterine contraction. Where injectable uterotonics are not available, misoprostol may be a useful alternative (Alfirevic *et al*, 2007).

#### *Recommendations*

**Women who are still anaemic at the time of delivery may require additional precautions for delivery, including delivery in an hospital setting, available intravenous access, blood group-and-save, active management of the third stage of labour and plans to deal with excessive bleeding. Suggested Hb cut-offs are <100 g/l for delivery in hospital and <95 g/l for delivery in an obstetrician-led unit (2B).**

### **6. Indications for and risks of blood transfusion**

Concerns about safety, high costs and availability of donor blood have promoted greater scrutiny of blood transfusion practice (Department of Health, 2007). Potential dangers of transfusion are numerous but most commonly arise from clinical and laboratory errors. In addition, specific risks for women of child-bearing age include the potential for transfusion-induced sensitization to red cell antigens, conferring a future risk of fetal haemolytic disease.

Massive Obstetric Haemorrhage (MOH) is widely recognized as an important cause of morbidity and mortality and requires prompt use of blood and components as part of appropriate management (Lewis, 2007). The RCOG green top guidelines (RCOG, 2009) comprehensively cover the multidisciplinary approach required, together with the implementation of intra-operative cell salvage in this setting as a transfusion sparing strategy. However outside the massive haemorrhage setting, audits indicate that a high proportion of blood transfusions administered in the postpartum period may be inappropriate, with underutilization of iron supplements (Butwick *et al*, 2009; Parker *et al*, 2009; So-Osman *et al*, 2010).

Clinical assessment and haemoglobin concentration is necessary postpartum to consider the best method of iron replacement. Where there is no bleeding, the decision to transfuse should be made on an informed individual basis. In fit, healthy, asymptomatic patients there is little evidence of the benefit of blood transfusion (American Society of Anesthesiologists Task Force, 1996), which should be reserved for women with continued bleeding or at risk of further bleeding, imminent cardiac compromise or significant symptoms requiring urgent correction.

If, after careful consideration, elective transfusion is required, women should be fully counselled about potential risks, including written information and consent should be obtained.

#### *Recommendation*

**Blood and components in massive obstetric haemorrhage should be used as indicated in a local multidisciplinary guideline and this should also include provision of intra-operative cell salvage where appropriate to reduce the use of donor blood (1A).**

In addition to guidelines for MOH, obstetric units should have guidelines for criteria for red cell transfusion in anaemic women who are not actively bleeding (1A).

The decision to transfuse women in the postpartum period should be based on careful evaluation including whether or not there is risk of bleeding, cardiac compromise or symptoms requiring urgent attention, considering oral or parenteral iron therapy as an alternative (1A).

Women receiving red cell transfusion should be given full information regarding the indication for transfusion and alternatives available. Consent should be sought and documented in the clinical notes (1A).

Prompt recognition of iron deficiency in the antenatal period followed by iron therapy may reduce the subsequent need for blood transfusions (1A).

## 7. Prevention of iron deficiency

### 7.1 Universal supplementation

The International Nutritional Anemia Consultative Group (INACG) and the WHO recommend universal supplementation with 60 mg/d of elemental iron, from booking (WHO) or from the second trimester (INACG) (Stolzfus & Dreyfuss, 1998; WHO, 2001). Evidence for this approach was first provided by the MotherCare Project in 1993, which reviewed the results of 24 well-conducted world-wide trials (Sloan *et al*, 1995). Virtually all studies demonstrated a positive effect of supplementation on maternal iron status. The Cochrane database confirmed these results, reviewing 49 trials involving 23,200 pregnant women. Although heterogeneity made results difficult to quantify between the studies, relative risk-reduction of anaemia at term was 30–50% for those receiving daily iron supplements, with or without folic acid (Peña-Rosas & Viteri, 2006; Peña-Rosas & Viteri, 2009).

**However** the studies reviewed in the Cochrane database provided insufficient information to draw conclusions about the impact on maternal and fetal outcomes, and randomized controlled studies have found conflicting evidence that maternal or neonatal health will benefit from correcting these deficits (Cogswell *et al*, 2003; Palma *et al*, 2008).

There are also other potential downsides to routine supplementation, to consider:

#### 7.1.1 Non-compliance.

Whilst studies of routine iron supplementation have shown improvements in Hb and ferritin, at present there is no good evidence of benefit when implemented as a large-scale programme through the primary health care system. Significant discrepancy exists between the impact of iron supplementation reported in the clinical trial setting and that observed in large-scale public health programmes. This is likely to be a combination of patients' and carers' behaviour; with, respectively, poor compliance due to lack of patient knowledge and concern about maternal anaemia and inadequate

counselling about the need for iron supplementation and its potential benefits and side-effects. Research has shown that drug compliance is inconsistent and often poor, despite relatively simple regimes and even where there is obvious life-threatening disease. It is worse in situations where there is no obvious ill health. In contrast, during clinical trials, patients are closely supervised, counselled and non-compliance kept to a minimum.

#### 7.1.2 Clinical hazards of routine supplementation.

There are potential clinical hazards of iron supplementation in already iron-replete women, including raised Hb with risk of placental insufficiency and secondary haemochromatosis in women with iron loading states. However these are mainly theoretical rather than practical considerations for short-term iron administration.

*Raised Hb.* The rheological status (haemoconcentration and elevated red cell aggregation) appears to have an important influence on the outcome of pregnancy (Sagen *et al*, 1982; Heilmann, 1987). There is a risk of elevated Hb with the use of iron supplements in non-anaemic women, particularly those given daily regimes from an early gestational age <20 weeks (Peña-Rosas & Viteri, 2009). This could represent excessive erythropoiesis but may have more to do with changes in plasma volume than with iron therapy. A U-shaped association has been observed between maternal Hb concentrations and birth weight. A large observational study of 54,382 pregnancies showed higher rates of perinatal death, low birth weights and preterm delivery in women with high (Hb >132 g/l) compared to intermediate Hb levels, at 13–19 weeks gestation (Murphy *et al*, 1986). Furthermore, a booking Hb of >145 g/l was associated with a 42% risk of subsequent hypertension in primiparous.

*Oxidant stress.* When products of oxygen are brought into contact with transition metals capable of changing valence, such as iron ( $\text{Fe}^{2+} \rightarrow \text{Fe}^{3+}$ ), reactive free radicals, the hydroxyl radicals are formed, which have the potential to damage cells and tissues (Halliwell & Gutteridge, 1999). Thus, tissue iron excess contributes to producing and amplifying the injury caused by free radicals as well as to modulating various steps involved in the inflammatory lesion.

The placenta is particularly susceptible to oxidative stress, being rich in mitochondria and highly vascular. Markers of oxidant stress (such as malondialdehyde) have been found to be significantly elevated in the placenta of women with regular iron supplementation in pregnancy (Devrim *et al*, 2006).

The intestinal mucosa is also vulnerable to oxidative damage, caused by the continuous presence of a relatively small amount of excess iron intake (Lund *et al*, 2001) and iron accumulation leading to intestinal abnormalities and injury has been observed in patients receiving therapeutic iron (Abraham *et al*, 1999). Previously iron-deficient pregnant women are potentially more susceptible, due to excessive iron absorption, particularly when given daily pharmacological doses of iron (Viteri, 1997).

### 7.1.3 Practical difficulties.

There are clear logistical problems associated with widespread use. These include cost and supply of iron tablets, cost and ability to deliver adequate supportive care and the potential risk of accidental overdose by children in the home. Iron ingestion has been the most common cause of paediatric poisoning deaths and doses as low as 60 mg/kg have proved fatal (Baker, 1989).

### 7.2 Alternative regimens

To avoid constant exposure of the intestinal mucosal cells to unabsorbed iron excess and oxidative stress and the risk of side effects and raised Hb with daily iron supplements, researchers have considered intermittent regimes, taken weekly or on alternate days. These appear to be as efficacious as daily regimes (Anderson, 1991; Institute of Medicine, 1993). However the extent to which these findings can be generalized needs to be determined and it may be that the response is not the same for all locations, depending upon variability in other background factors. Success has also been obtained with low dose daily regimes, such as 20 mg elemental iron (Makrides *et al*, 2003) given under controlled trial conditions.

## References

- Abraham, S.C., Yardley, J.H. & Wu, T.T. (1999) Erosive injury to the upper gastrointestinal tract in patients receiving iron medication: an under-recognized entity. *American Journal of Surgical Pathology*, **23**, 1241–1247.
- Adams, P.C., Reboussin, D.M., Press, R.D., Barton, J.C., Acton, R.T., Moses, G.C., Leindecker-Foster, C., McLaren, G.D., Dawkins, F.W., Gordeuk, V.R., Lovato, L. & Eckfeldt, J.H. (2007) Biological variability of transferrin saturation and unsaturated iron binding capacity. *The American Journal of Medicine*, **120**, 999.
- Al, R.A., Unlubilgin, E., Kandemir, O., Yalvac, S., Cakir, L. & Haberal, A. (2005) Intravenous versus oral iron for treatment of anemia in pregnancy: a randomized trial. *Obstetrics and Gynecology*, **106**, 1335–1340.
- Alfirevic, Z., Blum, J., Walraven, G., Week, A. & Winikoff, B. (2007) Prevention of postpartum hemorrhage with misoprostol. *International Journal of Gynecology and Obstetrics*, **99**, S198–S201.
- American Society of Anesthesiologists Task Force (1996) Practice guidelines for component therapy. *Anesthesiology*, **84**, 723–747.
- Anderson, S.A. (1991) *Guidelines for the Assessment and Management of Iron Deficiency in Women of Childbearing Age*. pp. 1–36. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Food Safety and Applied Nutrition.
- Arnold, D.L., Williams, M.A., Miller, R.S., Qiu, C. & Sorensen, T.K. (2009) Maternal iron deficiency anaemia is associated with an increased risk of

- abruption placentae – a retrospective case control study. *Journal of Obstetrics and Gynaecology Research*, **35**, 446–452.
- Asif, N., Hassan, K., Mahmud, S., Abbass Zaheer, H., Naseem, L., Zafar, T. & Shams, R. (2007) Comparison of serum ferritin levels in three trimesters of pregnancy and their correlation with increasing gravidity. *International Journal of Pathology*, **5**, 26–30.
- Baker, M.D. (1989) Iron. In: *Manual of Toxicologic Emergencies* (eds by E.K. Noji & G.D. Kelen), pp. 496–506. Year Book Medical Publishers, Chicago, IL, USA.
- Bayoumeu, F., Subiran-Buisset, C., Baka, N.-E., Legagneur, H., Monnier-Barbarino, P. & Laxenaire, M.C. (2005) Iron therapy in iron deficiency anaemia in pregnancy: intravenous route versus oral route. *European Journal of Obstetrics and Gynecology and Reproductive Biology*, **123**, S15–S19.
- Beard, J.L. (2008) Why iron deficiency is important in infant development. *Journal of Nutrition*, **138**, 2534–2536.
- Beard, J.L., Hendricks, M.K., Perez, E.M., Murray-Kolb, L.E., Berg, A., Vernon-Feagans, L., Irlam, J., Isaacs, W., Sivem, A. & Tomlinson, M. (2005) Maternal iron deficiency anemia affects postpartum emotions and cognition. *Journal of Nutrition*, **135**, 267–272.
- de Benoist, B., McLean, E., Egli, I. & Cogswell, M. (eds) (2008) *WHO Global Database on Anaemia. Worldwide Prevalence of Anaemia 1993–2005*. World Health Organization, Geneva, Switzerland.
- Bhandal, N. & Russell, R. (2006) Intravenous versus oral therapy for postpartum anaemia. *BJOG*, **113**, 1248–1252.

- Bothwell, T.H. (2000) Iron requirements in pregnancy and strategies to meet them. *American Journal Clinical Nutrition*, **72**, 257S–264S.
- Brabin, B.J., Hakimi, M. & Pelletier, D. (2001) An analysis of anemia and pregnancy-related maternal mortality. *Journal of Nutrition*, **131**, 604S–615S.
- Breyman, C. (2002) Iron supplementation during pregnancy. *Fetal and Maternal Medicine Review*, **13**, 1–29.
- Breyman, C., Gliga, F., Bejenariu, C. & Strzhova, N. (2007) Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. *International Journal of Gynecology & Obstetrics*, **101**, 67–73.
- British National Formulary (2010) Published jointly by BMJ Publishing Group Ltd and RPS Publishing, London.
- Broche, D.E., Gay, C., Armand-Branger, S., Grangeasse, L. & Terzibachian, J.J. (2005) Severe anaemia in the immediate post-partum period. Clinical practice and value of intravenous iron. *European Journal of Obstetrics and Gynecology and Reproductive Biology*, **123**, S21–S27.
- Butwick, A.J., Aleshi, P., Fontaine, M., Riley, E.T. & Goodnough, L.T. (2009) Retrospective analysis of transfusion outcomes in pregnant patients at a tertiary obstetric center. *International Journal Obstetric Anesthesia*, **18**, 302–308.
- Choi, J., Im, M. & Pai, S. (2000) Serum transferrin receptor concentrations during normal pregnancy. *Clinical Chemistry*, **46**, 725–727.
- Cogswell, M.E., Parvanta, I., Ickes, L., Yip, R. & Brittenham, G.M. (2003) Iron supplementation during pregnancy, anemia, and birthweight: a

## Recommendations

**Routine iron supplementation for all women in pregnancy is not recommended in the UK (1B).**

**An individual approach is preferable, based on results of blood count screening tests as well as identification of women at increased risk (1A).**

## Disclaimer

While the advice and information in these guidelines is believed to be true and accurate at the time of going to press, neither the authors, the British Society for Haematology nor the publishers accept any legal responsibility for the content of these guidelines.

## Acknowledgements and declarations of interest

All authors have contributed to the guideline and none have declared a conflict of interest. Acknowledgements also to Filipa Barroso, Clinical Research Fellow at Barts and the London & NHSBT and to Pauline Coser, Obstetric Haematology Midwife at University Hospitals of Leicester, who made contributions to the guideline.

- randomised controlled trial. *American Journal of Clinical Nutrition*, **78**, 773–781.
- Colomer, J., Colomer, C., Gutierrez, D., Jubert, A., Nolasco, A., Donat, J., Fernandez-Delgado, R., Donat, F. & Alvarez-Dardet, C. (1990) Anaemia during pregnancy as a risk factor for infant iron deficiency: report from the Valencia Infant Anaemia Cohort (VIAC) study. *Paediatric and Perinatal Epidemiology*, **4**, 196–204.
- Cunningham, F.G. & Pritchard, J.A. (1977) Hematologic disorders in pregnancy. In: *Perinatal Medicine: Management of the High Risk Fetus and Neonate* (eds by R.J. Bolognese & R.H. Schwarz), pp. 246–264. Williams & Wilkins, Baltimore, MD, USA.
- Department of Health (2007) *Better Blood Transfusion HSC 2007/001*. Department of Health, London. Crown copyright.
- Devrim, E., Tarham, I. & Erguder, I.B. (2006) Oxidant/antioxidant status of placenta, blood and cord samples from pregnant women supplemented with iron. *Reproductive Sciences*, **13**, 502–505.
- Dowdle, W. (1989) Centers for Disease Control: CDC Criteria for anemia in children and child-bearing-aged women. *Morbidity and Mortality Weekly Report*, **38**, 400–404.
- Ekiz, E., Agaoglu, L., Karakas, Z., Gurel, N. & Yalcin, I. (2005) The effect of iron deficiency anemia on the function of the immune system. *The Hematology Journal*, **5**, 579–583.
- Funk, F., Ryle, P., Canclini, C., Neiser, S. & Geisser, P. (2010) The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose. *Arzneimittel-Forschung*, **60**, 345–353.
- Gambling, L., Danzeisen, R., Gair, S., Lea, R.G., Charania, Z., Solanky, N., Jooty, K.D., Srari, S.K. & McArdle, H.J. (2001) Effect of iron deficiency on placental transfer of iron and expression of iron transport proteins in vivo and in vitro. *Biochemical Journal*, **356**, 883–889.
- Garn, S.M., Ridella, S.A., Petzold, A.S. & Falkner, F. (1981) Maternal hematologic levels and pregnancy outcomes. *Seminars in Perinatology*, **5**, 155–162.
- Gozzard, D. (2011) When is high-dose intravenous iron repletion needed? Assessing new treatment options. *Drug Design, Development and Therapy*, **5**, 51–60.
- Gregory, J.R., Foster, K., Tyler, H. & Wiseman, M. (1990) *The Dietary and Nutritional Survey of British Adults*. Her Majesty's Stationery Office, London.
- Haas, J.D. & Brownlie, T. (2001) Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship. *Journal of Nutrition*, **131**, 676S–690S.
- Hallberg, L., Bengtsson, C., Lapidus, L., Lindstedt, G., Lundberg, P.-A. & Hultén, L. (1993) Screening for iron deficiency: an analysis based on bone-marrow examinations and serum ferritin determinations in a population sample of women. *British Journal of Haematology*, **85**, 787–798.
- Halliwell, B. & Gutteridge, J.M. (1999) *Free Radicals in Medicine and Biology*, 2nd edn. Clarendon Press, Oxford.
- Heilmann, L. (1987) Blood rheology and pregnancy. *Baillière's Clinical Haematology*, **1**, 777–799.
- Insel, B.J., Schaefer, C.A., McKeague, I.W., Susser, E.S. & Brown, A.S. (2008) Maternal iron deficiency and the risk of schizophrenia in offspring. *Archives of General Psychiatry*, **65**, 1136–1144.
- Institute of Medicine (1993) *Iron Deficiency Anemia: Recommended Guidelines for the Prevention, Detection, and Management Among U.S. Children and Women of Childbearing Age*. National Academy Press, Washington DC.
- Komolafe, J.O., Kuti, O., Ijadunola, K.T. & Ogunniyi, S.O. (2003) A comparative study between intramuscular iron dextran and oral ferrous sulphate in the treatment of iron deficiency anaemia in pregnancy. *Journal Obstetrics and Gynaecology*, **23**, 628–631.
- Lewis, G. (ed) (2007). *The Confidential Enquiry into Maternal and Child Health (CEMACH). Saving Mothers' Lives: Reviewing Maternal Deaths to make Motherhood Safer—2003–2005*. The Seventh Report on Confidential Enquiries into Maternal Deaths in the United Kingdom. CEMACH, London.
- Lund, E.K., Fairweather-Tait, S.J., Warf, S.G. & Johnson, I.T. (2001) Chronic exposure to high levels of dietary iron fortification increases lipid peroxidation in the mucosa of the rat large intestine. *Journal of Nutrition*, **131**, 2928–2931.
- Lynch, S.R. (1997) Interaction of iron with other nutrients. *Nutritional Review*, **55**, 102–110.
- Lyseng-Williamson, K.A. & Keating, G.M. (2009) Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. *Drugs*, **69**, 739–756.
- Makrides, M., Crowther, C.A., Gibson, R.A., Gibson, R.S. & Skeaff, C.M. (2003) Efficacy and tolerability of low-dose iron supplements during pregnancy: a randomized controlled trial. *American Journal of Clinical Nutrition*, **78**, 145–153.
- McLean, E., Cogswell, M., Egli, I., Wojdyła, D. & de Benoist, B. (2009) Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System 1993–2005. *Public Health Nutrition*, **12**, 444–454.
- Milman, N., Bergholt, T., Byg, K., Eriksen, L. & Hvas, A.M. (2007) Reference intervals for haematological variables during normal pregnancy and postpartum in 434 healthy Danish women. *European Journal of Haematology*, **79**, 39–46.
- Murphy, J.F., O'Riordan, J., Newcombe, R.G., Coles, E.C. & Pearson, J.F. (1986) Relation of haemoglobin levels in first and second trimesters to outcome of pregnancy. *The Lancet*, **327**, 992–995.
- NHS Sickle Cell and Thalassaemia Screening Programme (2006) Standards for the Linked Antenatal and Newborn Screening Programme. <http://sct.screening.nhs.uk/getdata.php?id=11666>.
- NICE (2008) *Antenatal Care. Clinical Guideline CG62*. National Institute for Health and Clinical Excellence, London.
- Palma, S., Perez-Iglesias, R., Prieto, D., Pardo, R., Llorca, J. & Delgado-Rodriguez, M. (2008) Iron but not folic acid supplementation reduces the risk of low birthweight in pregnant women without anaemia: a case control study. *Journal of Epidemiology Community Health*, **62**, 120–124.
- Parker, J., Thompson, J. & Stanworth, S. (2009) A retrospective one-year single-centre survey of obstetric red cell transfusions. *International Journal of Obstetric Anesthesia*, **18**, 309–313.
- Pasricha, S., Flecknoe-Brown, S. & Allen, K. (2010) Diagnosis and management of iron deficiency anaemia: a clinical update. *Medical Journal of Australia*, **193**, 525–532.
- Peña-Rosas, J.P. & Viteri, F.E. (2006) Effects of routine oral iron supplementation with or without folic acid for women during pregnancy. *Cochrane Database of Systematic Reviews*, **3**, CD004736.
- Peña-Rosas, J.P. & Viteri, F.E. (2009) Effects and safety of preventive oral iron or iron+folic acid supplementation for women during pregnancy. *Cochrane Database of Systematic Reviews*, **4**, CD004736.
- Perewusnyk, G., Huch, R., Huch, A. & Breyman, C. (2002) Parenteral iron therapy in obstetrics: 8 years experience with iron-sucrose complex. *British Journal of Nutrition*, **88**, 3–10.
- Perez, E.M., Hendricks, M.K., Beard, J.L., Murray-Kolb, L.E., Berg, A., Tomlinson, M., Irlam, J., Isaacs, W., Njengele, T., Sive, A. & Vernon-Feagans, L. (2005) Mother-infant Interactions and infant development are altered by maternal iron deficiency anemia. *Journal of Nutrition*, **135**, 850–855.
- Prendiville, W., Harding, J.E., Elbourne, D.R. & Stirrat, G.M. (1988) The Bristol third stage trial: active versus physiological management of the third stage of labour. *British Medical Journal*, **297**, 1295–1300.
- Puolakka, J., Jänne, O. & Vihko, R. (1980) Evaluation by serum ferritin assay of the influence of maternal iron stores on the iron status of newborns and infants. *Acta Obstetrica et Gynecologica Scandinavica*, **59**, 53–56.
- Ramsey, M., James, D. & Steer, P. (2000) *Normal Values in Pregnancy*, 2nd edn. WB Saunders, London.
- RCOG (2007) *Blood Transfusion in Obstetrics. RCOG Green-top Guideline 47*. Royal College of Obstetricians and Gynaecologists, London.
- RCOG (2009) *Postpartum Haemorrhage, Prevention and Management. RCOG Green-top Guideline 52*. Royal College of Obstetricians and Gynaecologists, London.
- Revez, L., Gyte, G.M.L. & Cuervo, L.G. (2007) Treatments for iron-deficiency anaemia in pregnancy. *Cochrane Database of Systematic Reviews*, **2**, CD003094.
- Rogers, J., Wood, J., McCandlish, R., Ayers, S., Truesdale, A. & Elbourne, D. (1998) Active versus expectant management of the third stage of labour: the Hinchinbrooke randomised controlled trial. *Lancet*, **351**, 693–699.
- Ryan, K., Bain, B. & Worthington, D. (2010) Significant haemoglobinopathies: guidelines for screening and diagnosis. *British Journal of Haematology*, **149**, 35–49.
- Sagen, N., Koller, O. & Haram, K. (1982) Haemoglobin concentration in severe preeclampsia. *British Journal of Obstetrics and Gynaecology*, **89**, 802–805.

- Schifman, R.B., Thomasson, J.E. & Evers, J.M. (1989) Role of ferritin supported in diagnosis of anemias of pregnancy. *American Journal Obstetrics and Gynecology*, **161**, 258–259.
- Scholl, T.O. & Hediger, M.L. (1994) Anemia and iron-deficiency anemia: compilation of data on pregnancy outcome. *American Journal of Clinical Nutrition*, **59**, S492–S501.
- Seid, M.H., Derman, R.J., Baker, J.B., Banach, W., Goldberg, C. & Rogers, R. (2008) Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. *American Journal of Obstetrics and Gynecology*, **199**, 435.
- Skikne, B. & Baynes, R.D. (1994) Iron absorption. In: *Iron Metabolism in Health and Disease* (eds by J.H. Brock, J.W. Halliday, M.J. Pippard & L.W. Powell), pp. 151–187. Saunders, London.
- Sloan, N.L., Jordan, E.A. & Winikoff, B. (1995) *Does Iron Supplementation make a Difference? MotherCare Working Paper no. 15*. MotherCare Project, John Snow, Inc., Arlington, VA.
- Solomons, N.W. & Schumann, K. (2004) Intramuscular administration of iron dextran is inappropriate for treatment of moderate pregnancy anaemia, both in intervention research on underprivileged women and in routine prenatal care provided by public health services. *American Journal of Clinical Nutrition*, **79**, 1–3.
- So-Osman, C., Cicilia, J., Brand, A., Schipperus, M., Berning, B. & Scherjon, S. (2010) Triggers and appropriateness of red blood cell transfusions in the postpartum patient – a retrospective audit. *Vox Sanguinis*, **98**, 65–69.
- Stolzhus, R.J. & Dreyfuss, M. (1998) *Guidelines for the Use of Iron Supplementation to Prevent and Treat Iron Deficiency Anemia*. International Nutritional Anemia Consultative Group (INACG). ILSI Press, Washington, DC.
- Tapiero, H., Gaté, L. & Tew, K.D. (2001) Iron: deficiencies and requirements. *Biomedicine and Pharmacotherapy*, **55**, 324–332.
- Van den Broek, N.R., Letsky, E.A., White, S.A. & Shenkin, A. (1998) Iron status in pregnant women: which measurements are valid? *British Journal of Haematology*, **103**, 817–824.
- Van Wyk, D.B. & Martens, M.G. (2007) Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anaemia: a randomized controlled trial. *Obstetrics & Gynecology*, **110**, 267–278.
- Viteri, F.E. (1997) Iron supplementation for the control of iron deficiency in populations at risk. *Nutritional Reviews*, **55**, 195–209.
- WHO (1992) *The Prevalence of Anaemia in Women: A Tabulation of Available Information*. World Health Organization, Geneva, Switzerland. (unpublished document WHO/MCH/MSM/92.2; available upon request from Division of Reproductive Health, World Health Organization, 1211 Geneva 27, Switzerland).
- WHO (2001) *Iron Deficiency Anaemia: Assessment, Prevention and Control*. WHO/NHD/01.3, World Health Organization, Geneva, Switzerland.